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Abstract
Background: Diagnosing polycystic ovary syndrome (PCOS) during adolescence is challenging because features of
normal pubertal development overlap with adult diagnostic criteria. The international evidence-based PCOS
Guideline aimed to promote accurate and timely diagnosis, to optimise consistent care, and to improve health
outcomes for adolescents and women with PCOS.
Methods: International healthcare professionals, evidence synthesis teams and consumers informed the priorities,
reviewed published data and synthesised the recommendations for the Guideline. The Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE) framework was applied to appraise the evidence quality and the
feasibility, acceptability, cost, implementation and strength of the recommendations.
Results: This paper focuses on the specific adolescent PCOS Guideline recommendations. Specific criteria to improve
diagnostic accuracy and avoid over diagnosis include: (1) irregular menstrual cycles defined according to years post-
menarche; > 90 days for any one cycle (> 1 year post-menarche), cycles< 21 or > 45 days (> 1 to < 3 years post-
menarche); cycles < 21 or > 35 days (> 3 years post-menarche) and primary amenorrhea by age 15 or > 3 years
post-thelarche. Irregular menstrual cycles (< 1 year post-menarche) represent normal pubertal transition. (2)
Hyperandrogenism defined as hirsutism, severe acne and/or biochemical hyperandrogenaemia confirmed
using validated high-quality assays. (3) Pelvic ultrasound not recommended for diagnosis of PCOS within 8
years post menarche. (4) Anti-Müllerian hormone levels not recommended for PCOS diagnosis; and (5) exclusion of other
disorders that mimic PCOS. For adolescents who have features of PCOS but do not meet diagnostic criteria an ‘at risk’ label
can be considered with appropriate symptomatic treatment and regular re-evaluations. Menstrual cycle re-evaluation can
occur over 3 years post menarche and where only menstrual irregularity or hyperandrogenism are present initially, evaluation
with ultrasound can occur after 8 years post menarche. Screening for anxiety and depression is required and assessment of
eating disorders warrants consideration. Available data endorse the benefits of healthy lifestyle interventions to prevent
excess weight gain and should be recommended. For symptom management, the combined oral contraceptive pill and/or
metformin may be beneficial.
Conclusions: Extensive international engagement accompanied by rigorous processes honed both diagnostic criteria and
treatment recommendations for PCOS during adolescence.
Keywords: Adolescents, Girls, Polycystic ovary syndrome, Evidence-based, Diagnosis, Treatment
© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: alexia.pena@adelaide.edu.au
1Discipline of Paediatrics, The University of Adelaide Robinson Research
Institute and Endocrine Department, Women’s and Children’s Hospital, 72
King William Road, North Adelaide, SA 5006, Australia
Full list of author information is available at the end of the article
Peña et al. BMC Medicine           (2020) 18:72 
https://doi.org/10.1186/s12916-020-01516-x
Background
Polycystic ovary syndrome (PCOS) is the most common
endocrine condition affecting between 8 and 13% of
women of reproductive age [1] and 6–18% of adolescent
girls [2, 3] depending on the diagnostic criteria used and
the population studied [4–6]. Adolescence, as defined by
the World Health Organisation, is the period between
10 and 19 years of age that includes significant and crit-
ical changes in growth, development and puberty.
Diagnosis of PCOS during adolescence is both contro-
versial and challenging due to the overlap of normal pu-
bertal physiological changes (irregular menstrual cycles,
acne and polycystic ovarian morphology on pelvic ultra-
sound) with adult PCOS diagnostic criteria. These
challenges have been acknowledged in adult and paedi-
atric consensus statements [4–10]. Specifically, chal-
lenges include the risk of under-diagnosis, delayed and/
or poor diagnosis experiences [11], and over-diagnosis as
well as the additional risk of the use of inconsistent non-
evidence-based approaches in the diagnosis and manage-
ment of PCOS among specialists, general practitioners
and allied health professionals [12–14]. These challenges
are exacerbated by the lack of robust evidence. For ex-
ample, ‘only adolescents’ studies are limited and subopti-
mal in quality. Further, adult studies that include
adolescents do not specify the number of adolescents or
time post menarche, which is critical information to
determine the evolution of normal pubertal physio-
logical changes [15]. Lastly, relevant consensus state-
ments are often not specific to adolescents and/or not
based on robust high-level evidence and/or rigorous
processes, indicating the need for high quality,
evidence-based guidelines [4, 5, 7, 10].
The aim of the first International Evidence-based
Guideline for the Assessment and Management of PCOS
(‘the Guideline’) was to promote the accurate diagnosis
of PCOS, optimal consistent care, the prevention of
complications and improved patient health outcomes
from adolescence to adulthood [6]. The term ‘adoles-
cence’ in the Guideline was defined as the period be-
tween 10 and 19 years of age according to the World
Health Organisation. However, based on evidence, those
who were within a gynaecological age of 8 years or less
than 8 years post menarche were also identified in the
recommendations.
This paper focuses specifically on the adolescent recom-
mendations from the Guideline and examines the evidence
and rationale supporting these recommendations. We dis-
cuss the importance of avoiding missed diagnosis, of delayed,
under- or over-diagnosis, and of evidence-based manage-
ment to address PCOS symptoms in adolescents. Addition-
ally, we expand on approaches to identify girls ‘at risk’ of
PCOS but not yet diagnosed, including the need for future
follow-up.
Methods
Best practice evidence-based guideline development
methodology was applied [16–18], as detailed in the full
Guideline and Technical Report that are freely available
[19, 20]. The Guideline development process engaged
health professional societies and consumer organisa-
tions, multidisciplinary experts including paediatricians
and gynaecologists who are experts in adolescent gynae-
cology, and women with PCOS, who were directly in-
volved at all stages.
As previously outlined, a six-continent international
advisory and project board, a multidisciplinary inter-
national guideline development group, and consumer
and translation committees provided governance of the
Guideline processes [6]. The engaged, international
society-nominated panel provided experts in endocrin-
ology, paediatrics, gynaecology, reproductive endocrin-
ology, obstetrics, and public health, alongside consumers
and project management, evidence synthesis, and trans-
lation experts. A total of 37 societies and organisations
representing 71 countries were engaged in a 15-month
process. The Guideline addressed 60 prioritised clinical
questions encompassing 40 evidence-based reviews and
20 narrative reviews, most of which sought to identify
evidence relevant to adolescents. The detailed descrip-
tion of the methods of development of each of the 60
questions and subsequent reviews is extensive and can-
not be provided herein; therefore, for each topic out-
lined, we have provided guidance to the corresponding
section of the Guideline Technical Report [20]. Ap-
praisal of Guidelines for Research and Evaluation
(AGREE) II-compliant processes were followed, with
extensive evidence synthesis. The Grading of Recom-
mendations, Assessment, Development, and Evaluation
(GRADE) framework was applied across evidence qual-
ity, desirable and undesirable consequences, feasibility,
acceptability, cost, implementation and, ultimately, rec-
ommendation strength [16]. Evidence-based recommen-
dations were formulated on the basis of an extensive and
detailed review of all available evidence and following a
rigorous, structured GRADE processes as well as exten-
sive international peer review.
Importantly, extensive engagement with stakeholders,
including women with PCOS, and the multidisciplinary
panels informed the Guideline research questions and
highlighted the impact of PCOS across the lifespan. It
also highlighted the importance of accurate and early
diagnosis to optimise education, treatment and the pre-
vention of longer-term complications.
Categories of recommendations are described in
Table 1 and included evidence-based recommendations,
consensus recommendations and practice points [6]. Key
recommendation terms include ‘should’, ‘could’ and
‘should not’. These terms are informed by the nature of
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the recommendation (evidence or consensus), the
GRADE framework and evidence quality, and are inde-
pendent descriptors reflecting the judgement of the
multidisciplinary Guideline Development Group (GDG),
including consumers (women with PCOS). These terms
refer to overall interpretation and practical application
of the recommendation, balancing benefits and harms.
‘Should’ is used where benefits of the recommendation
exceed harms and where the recommendation can be
trusted to guide practice. ‘Could’ is used where either
the quality of evidence was limited or the available stud-
ies demonstrate little clear advantage of one approach
over another, or where the balance of benefits to harm
was unclear. ‘Should not’ is used where there is either a
lack of appropriate evidence or the harms may outweigh
the benefits.
The GRADE quality of the recommendation was de-
termined by the GDG from structured consideration of
the GRADE framework [16], including desirable effects,
undesirable effects, balance of effects, resource require-
ments and cost effectiveness, equity, acceptability, and
feasibility. The GRADE approach included Conditional
recommendation against the option; Conditional recom-
mendation for either the option or the comparison; Con-
ditional recommendation for the option; and Strong
recommendation for the option.
The quality of the evidence was categorised according
to information about the number and design of studies
addressing the outcome; judgments about the quality of
the studies and/or synthesised evidence such as risk of
bias, inconsistency, indirectness, imprecision and any
other considerations that may influence the quality of
evidence; key statistical data; and classification of the im-
portance of the outcomes (Table 2). The quality of evi-
dence reflects the extent to which our confidence in an
estimate of the effect is adequate to support a particular
recommendation [18] and was largely determined by the
expert evidence synthesis team.
The GRADE recommendations affirm that the quality
of evidence is a continuum; any discrete categorisation
involves a degree of arbitrariness [16]. Nevertheless,
the advantages of simplicity, transparency and vivid-
ness outweigh these limitations [18]. Consensus rec-
ommendations do not have a quality of evidence
rating (as no evidence was found) and practice points
do not have a ‘GRADE’ rating as they arose from dis-
cussion of evidence-based or clinical consensus
recommendations (Table 1). The meaning or inter-
pretation of the GRADE quality of recommendations
is provided in Table 3 [16, 21].
Following completion of these stages, the draft guide-
line was distributed to all 37 partnering societies, includ-
ing paediatric endocrine societies, and to specifically
formulated special interest groups in each society pro-
viding review and feedback. Evidence was required to
support any requests for recommendation modifications.
The feedback and responses are available under the
Guideline supporting documents (Public Consultation
Comments and Developer Responses) [19]. These were
reviewed by a specially convened paediatric guideline
committee (including the authors of this paper). This
process further refined the recommendations, which in
turn were approved by all societies.
Results
The full Guideline is summarised by Teede et al. [6] and
provides recommendations on the five areas covered by
the GDGs, namely diagnosis and comorbidities risk as-
sessment, assessment and treatment of emotional well-
being, lifestyle, pharmacological treatment for non-
fertility indications, and assessment and treatment of
infertility.
This paper examines the recommendations related to
adolescents, including diagnosis, assessment and treat-
ment of emotional wellbeing, and lifestyle and pharma-
cological treatment for non-fertility indications. We do
not cover assessment and treatment of infertility, which
can be found in the Guideline. The recommendations
provided here include evidence-based recommendations,
consensus recommendations and practice points, with
most of the evidence-based recommendations in adoles-
cents being related to the treatment of PCOS.




Evidence-based recommendations are made where
evidence is sufficient to inform a recommendation
made by the guideline development group
Consensus
recommendations
Clinical consensus recommendations are made in
the absence of adequate evidence on PCOS; these
are informed by evidence in other populations and
is made by the guideline development group, using
rigorous and transparent processes
Practice points Clinical practice points are made where evidence
was not sought and where important clinical issues
arose from discussion of evidence-based or clinical
consensus recommendations
Table 2 Categories of quality (certainty) of evidence (adapted
from GRADE [16])
High Very confident that the true effect lies close to that of the
estimate of the effect
Moderate Moderate confidence in the effect estimate – the true effect
is likely to be close to the estimate of the effect, but there is
a possibility that it is substantially different
Low Limited confidence in the effect estimate – the true effect
may be substantially different from the estimate of the effect
Very low Very little confidence in the effect estimate – the true effect
is likely to be substantially different from the estimate of
effect
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Diagnosis
Key changes within the Guideline recommendations in-
clude the elimination of specific unnecessary tests and
the importance of identifying adolescents ‘at risk’ of
PCOS. The changes also aim to avoid misdiagnosis or
delayed, under- or over-diagnosis. Adolescent consensus
recommendations for PCOS diagnosis are based on the
best-quality available evidence and its limitations.
Criteria required
1. Irregular menstrual cycles and ovulatory dysfunction
Clear definition of irregular menstrual cycles according
to time post menarche was the first strong consensus
recommendation as there was limited evidence to for-
mulate an evidence-based recommendation (Table 4).
When irregular menstrual cycles are present, a diagnosis
of PCOS should be considered.
Whilst the literature search on the question “At what
time point after the onset of menarche do irregular men-
strual cycles indicate ongoing menstrual dysfunction?”
revealed 36 studies (see Section 1.1 in the Technical Re-
port), these did not meet the selection criteria for the
systematic review framework as they did not report on
the duration of menstrual irregularity and/or diagnosis
of PCOS. Hence, relevant information from diverse stud-
ies was extracted from the literature in a narrative re-
view format. This informed the consensus
recommendation based on the evidence on menstrual
cycles in healthy girls [22–32].
This recommendation was also informed by previous
available guidelines, multidisciplinary expertise, con-
sumer perspectives, international feedback, and the po-
tential for both over and delayed diagnosis when
assessing this diagnostic feature in PCOS. This recom-
mendation considered available data on normal physio-
logical events during adolescence such as menstrual
cycle interval variations according to time post menar-
che and the fact that anovulation is a common physio-
logical event in early post menarcheal years [22–34].
Physiological maturation of the hypothalamic–pituitary
ovarian axis occurs over the years and ovulation and
menstrual cycles in adolescents may not match those of
women in reproductive age [26, 28, 33, 34]. More spe-
cific cut-offs aligned with gynaecological maturity were
provided in comparison to previous guidelines [4, 5, 9].
Another practice point from the Guideline is that
ovarian dysfunction can still occur in adolescents or
women with regular menstrual cycles and, if anovulation







option (test or treatment)
Conditional (weak)
recommendation for





Consumers Most people in your
situation would want
the recommended
course of action and
only a small
proportion would not
The majority of people in
your situation would want
the recommended course
of action but some would
not
There is considerable lack
of clarity over whether the
majority of people in your
situation would want the
recommended course of
action or not
The test or intervention
should only be considered
by patients and clinicians
within the setting of a

















choices will be appropriate
for different patients and
that greater effort is




Decision aids and shared
decision-making are im-
portant here
The test or intervention
should only be considered
by patients and clinicians
within the setting of a
















Policy-makers need to be
aware of the need for




a Strong recommendations based on high quality evidence will apply to most patients for whom these recommendations are made, but they may not apply to all
patients in all conditions; no recommendation can take into account all of the often-compelling unique features of individual patients and clinical circumstances
b A clinical practice point is developed by the Guideline Development Group to support recommendations; advice can be provided to enhance shared decision-
making and on factors to be considered in implementing a specific test or intervention
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Calculated free testosterone, free androgen index or
bioavailable testosterone should be used to assess bio-
chemical hyperandrogenism in the diagnosis of PCOS.
This was the only strong evidence-based recommenda-
tion of low GRADE quality for biochemical testing for
hyperandrogenism, including one study in adolescents
[35]. This recommendation was determined after exam-
ination of the literature showing that androgen levels in
adolescents reach adult levels around the time of menar-
che. Seven studies evaluated the most effective measure
to diagnose PCOS-related hyperandrogenism (biochem-
ical) [35–41], with only one of these studies performed
in adolescents, including 89 subjects (26 with girls with
PCOS and 63 controls) [35] (see Section 1.2 in the Tech-
nical Report).
There were two conditional evidence-based recommen-
dations of low GRADE quality derived from studies in
adult women that reported on the diagnostic accuracy of
different hormone markers to detect PCOS [36–41]. One
study compared the diagnostic accuracy of different types
of assay to detect PCOS but did not include adolescents
[42]. High-quality assays, such as liquid chromatography–
mass spectrometry and extraction/chromatography im-
munoassays, should be used for the most accurate
assessment of total or free testosterone in PCOS. Andro-
stenedione and dehydroepiandrosterone sulfate (DHEAS)
provide limited additional information in the diagnosis of
PCOS, however they could be considered if total or free
testosterone are not elevated. Androstenedione and
DHEAS are more useful in excluding other causes of
hyperandrogenism. Androstenedione is elevated in non-
classical adrenal hyperplasia. DHEAS is a predominantly
adrenal androgen and mild elevations can be seen in
PCOS, whereas significant elevations and/or virilisation
can be seen in androgen-secreting adrenal tumours.
Important practice points included avoiding the as-
sessment of biochemical hyperandrogenism in women
on hormonal contraception (a drug withdrawal of 3
months is recommended, addressing needs for contra-
ception through other means). Careful interpretation of
androgen levels is needed by considering the reference
ranges of the laboratory used and normal values derived
from a well-phenotyped population, including age and
pubertal-specific stages. Additionally, the guidelines
noted that, when clinical hyperandrogenism is not de-
tected, biochemical hyperandrogenism should be deter-
mined using appropriate high-quality assays.
b. Clinical hyperandrogenism
A comprehensive history and physical examination
should be completed for symptoms and signs of clinical
hyperandrogenism, which in adolescents include severe
acne and hirsutism; this was the first strong consensus
recommendation because no evidence-based recommen-
dation in relation to clinical hyperandrogenism was
available. This recommendation was based on the fact
that mild comedonal acne is common in adolescent girls
but moderate or severe comedonal acne (i.e. 10 or more
facial lesions) in early puberty or moderate to severe in-
flammatory acne during the peri-menarcheal years is un-
common (less than 5%) and is more likely to relate to
clinical hyperandrogenism [43–45]. In addition, there
are no studies in adolescents evaluating alopecia in the
context of PCOS.
Standardised visual scales are preferred when assessing
hirsutism, such as the modified Ferriman–Gallwey score
(mFG), with a level ≥ 4–6 indicating hirsutism, depend-
ing on ethnicity, and acknowledging that self-treatment
is common and can limit clinical assessment. This sec-
ond strong consensus recommendation was based on
the most common visual assessment tool, the mFG [46,
47]. This tool was first used in a cohort of women that
included 75 females aged between 15 and 24 years, yet
the number of adolescents per se was not specified [46].
mFG evaluates terminal hairs (hairs that would grow
more than 5mm in length if left intact and are usually
pigmented and medullated) in 9 primarily androgen-
dependent areas – upper lip, chin and neck, upper chest
(excluding the nipples), upper abdomen (above the um-
bilicus), lower abdomen, thighs (front and/or back),
upper back, lower back, and upper arms. Each area is
visually scored from zero (no terminal hair visible) to
four (terminal hair consistent with a well-developed
male) [46, 47]. Inquiry regarding self-treatment should
be made and recorded in the examination. The defin-
ition of ‘abnormal’ in hirsutism is controversial and
Table 4 Definition of irregular menstrual cycles in adolescents
according to time post menarche
Time post
menarche
Definition of irregular menstrual cycles
Less than 1 year
post menarche
Irregular menstrual cycles are normal pubertal
transition
> 1 to < 3 years
post menarche
< 21 or > 45 days
> 3 years post
menarche
< 21 or > 35 days or < 8 cycles per year
More than 1 year
post menarche
> 90 days for any one cycle
Primary amenorrhoea by age 15 years or > 3 years
post thelarche (breast development)
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varies across ethnicities. The original Ferriman–Gallwey
cut-off was 4–6 and this later evolved in the literature to
an arbitrary cut-off of 6–8 based on the 95th percentile
of unselected women (which likely included women with
PCOS) [48]. Lower mFG cut-offs are generated in stud-
ies where the lower 85th to 90th percentile cut-offs are
used to define ‘normal’ or from cluster analysis including
other features of PCOS (> 3 in White and Black women
[49], > 5 in Mongoloid Asian (Han Chinese) women
[50]). Over 50% of women with mFG scores of 3–5 and
over 70–90% of women with mFG scores > 5 have ele-
vated androgens and/or PCOS. Of note, these cut-offs
sought accurate diagnosis by avoiding under-diagnosis
and reflected evidence on clustering of hyperandrogen-
ism with other PCOS features, rather than arbitrary per-
centile cut-offs. However, the cut-offs are based mainly
on studies in adult women, not adolescents (see Section
1.3 in the Technical Report). Of note, three well-
designed population studies, including a total of 889
healthy adolescents and some adolescents with PCOS
(12.5–17.5 years), have demonstrated that higher hirsut-
ism scores are related to higher testosterone levels [2,
51, 52]. Additionally, a longitudinal study in adolescents
showed an increase in hirsutism scores with age and
time post menarche [53].
Health professionals should be aware of the potential
negative psychosocial impact of clinical hyperandrogen-
ism. Reported unwanted excess hair growth should be
considered important, regardless of apparent clinical se-
verity. This third consensus recommendation was based
on a systematic review of quality of life and included a
study with 97 adolescents with PCOS [54].
Investigations not recommended
1. Pelvic ultrasound for PCOS diagnosis
Pelvic ultrasound should not be used for the diagnosis
of PCOS in those with a gynaecological age of < 8 years
(< 8 years post menarche) due to the high incidence of
multi-follicular ovaries in this life stage. This was a
strong consensus recommendation and not an evidence-
based recommendation because reliable data regarding
longitudinal ovarian morphology are limited. Addition-
ally, the specific 8 years post-menarche cut-off was based
on a consensus recommendation by the GDG, consulted
with international societies and refined after inter-
national peer review. The recommendation also consid-
ered 15 studies evaluating the most effective ultrasound
criteria to diagnose PCOS in women using various mea-
sures and thresholds for ovarian volume and follicle
number. However, adult PCOS criteria have been de-
rived from transvaginal ultrasounds, which should be
avoided in females not yet sexually active. Three of these
15 studies included adolescents (181 with PCOS and 137
controls), two of which used trans-abdominal ultrasound
and one used trans-rectal ultrasound (68 with PCOS and
26 controls) [35, 55, 56]. The 12 studies included women
aged between 18 and 40 years (average minimum and
maximum ages 24.9 and 31.2 years, respectively) (see
Section 1.4 in the Technical Report). Additionally, this
recommendation considered the physiological matur-
ation of the hypothalamic–pituitary ovarian axis [26, 28,
33, 34].
Furthermore, a polycystic ovarian morphology may
represent a marker of PCOS or may be normal in young
women. A population study showed a higher prevalence
of polycystic ovarian morphology in very young women
without menstrual irregularity and hyperandrogenism
(although this study used older criteria for polycystic
ovarian morphology and none of the criteria for polycys-
tic ovarian morphology have used age base cut-offs)
[57]. A small longitudinal study of healthy adolescents at
2 to 4 years post menarche suggested that polycystic
ovarian morphology is common and not associated with
reproductive dysfunction [58]. Due to this overlap be-
tween follicle numbers per ovary in normal adolescents
and in those with other features of PCOS, the adult
polycystic ovarian morphology criteria are likely inaccur-
ate for the ultrasound diagnosis of PCOS during adoles-
cence. Additionally, the use of pelvic ultrasound will
increase the risk of PCOS over-diagnosis during adoles-
cence. Lastly, the Guideline also highlighted the signifi-
cant evolution of ultrasound technologies and the
evolving number of follicles recommended for diagnosis
even in adult women, a factor that contributed to the
recommendation to avoid the use of pelvic ultrasound in
the diagnosis of PCOS in females at less than 8 years
post menarche. The term ‘adolescents’ was avoided in
this recommendation and the terms ‘gynaecological age’
or ‘time post menarche’ were used to align with inter-
national paediatric guidelines describing menstrual ir-
regularity [4, 32]. A gynaecological age of < 8 years as
the cut-off was in part chosen based on normative
models suggesting that the maximum ovarian volume is
reached at age 20 [59]. There are no large studies across
the lifespan to validate normal ovarian development with
normal reference ranges. Some studies indicate that
ovarian volume changes over time with increased antral
follicles and stroma; ovarian size increases from ages 9
to 11, reaching the maximum volume at age 20 [59–62].
Although pelvic ultrasound is not indicated for PCOS
diagnosis in adolescents, it can be used to investigate
other possible uterine or ovarian abnormalities in ado-
lescent girls such as those that present with primary
amenorrhoea.
2. Anti-Müllerian hormone (AMH)
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AMH is a polypeptide of the transforming growth
factor-β family secreted by granulosa cells of the pre-
antral and small antral ovarian follicles. Hence, AMH has
been evaluated in the diagnosis of PCOS, especially in sit-
uations where pelvic ultrasound is not feasible [63, 64].
AMH levels should not be used as an alternative for
the detection of polycystic ovarian morphology or as a
single test for the diagnosis of PCOS. This evidence-
based recommendation (conditional and of low GRADE
quality) was based on 29 studies, including a systematic
review [65] evaluating whether AMH was effective for
the diagnosis of PCOS or polycystic ovarian morphology.
Six of the 29 studies [58, 66–70] were performed in ado-
lescents from different countries and included 375 ado-
lescent girls diagnosed with PCOS and 639 controls.
One study was in overweight/obese adolescents [70] and
one study did not specify body mass index (BMI) [69].
Only one study in adolescents evaluated the diagnostic
accuracy of AMH for polycystic ovarian morphology
[58] (see Section 1.5 in the Technical Report).
Although serum AMH levels in adolescents and adult
women with both polycystic ovarian morphology and
PCOS are significantly higher than in those without
these features in all the studies included [58, 65–70],
there was significant overlap in levels as well as hetero-
geneity between studies with regards to assays, life stage
and phenotypes of the populations studied, including the
use of different PCOS criteria.
There is emerging evidence that, with improved stand-
ardisation of assays and established cut-off levels based
on large populations of different ages and ethnicities,
AMH assays will become more accurate in the detection
of polycystic ovary morphology.
Exclusion of other conditions
The diagnosis of PCOS is a diagnosis of exclusion – all
other aetiologies that can cause menstrual irregularities
and/or hyperandrogenism must be excluded, regardless
of the fact that some aetiologies are less common in ad-
olescents. The most important cause of amenorrhoea in
a sexually active adolescent is pregnancy. Menstrual ir-
regularity alone could be due to gonadotropin deficiency
caused by functional hypothalamic amenorrhoea, sec-
ondary deficiency due to any systemic cause, or to a pri-
mary gonadotropin defect. Many conditions can lead to
hyperandrogenism; the most common albeit rare condi-
tion (outside of PCOS) is non-classic congenital adrenal
hyperplasia (NCAH), characterised by a marked eleva-
tion of androgen levels. Deficiency of 21-hydroxylase,
due to mutations in the 21-hydroxylase (CYP21A2) gene,
is the most common type of NCAH seen. The
prevalence of NCAH is reported as 1 in 1000 but is even
more frequent in certain ethnic groups [71]. Diagnosis
of NCAH is suspected if an adolescent girl has
clitoromegaly and/or an early-morning, follicular phase
17-hydroxyprogesterone (17-OHP) level of > 200 ng/dl
(> 6 nmol/L) and confirmed at 17-OHP levels of > 35
nmol/L (1000–1500 ng/dl) 60 min after administration
of 250 μg of synthetic adrenocorticotropic hormone or
synacthen [72].
Hypothyroidism, hyperprolactinemia, glucocorticoid
excess due to Cushing’s disease, glucocorticoid resist-
ance, and androgen-secreting ovarian or adrenal tu-
mours can cause menstrual irregularity and/or
hyperandrogenism [73]. A thorough history and physical
examination to look for signs of hypothyroidism, galac-
torrhoea, glucocorticoid excess or virilisation are import-
ant in the evaluation of an adolescent girl with suspected
PCOS. Measurement of serum thyroid stimulating hor-
mone, prolactin, gonadotropins, androgen and/or fol-
licular phase 17-OHP levels is required to exclude these
conditions. If the androgen levels are twice above the
upper limit of the reference range, imaging is also re-
quired to assess the ovary and/or adrenals. An overnight
dexamethasone suppression test or midnight salivary
cortisol estimation is required to exclude Cushing’s syn-
drome, though importantly only where the condition is
clinically suspected.
Adolescents ‘at risk’ of PCOS
A practice point for this section is that, for adolescents
who have features of PCOS but do not meet the diag-
nostic criteria, the ‘at risk’ of PCOS label could be con-
sidered and reassessment is advised at or before full
reproductive maturity. This timing is at 3 years post me-
narche in relation to menstrual cycle irregularity and at
8 years post menarche in relation to the use of pelvic
ultrasound to identify a polycystic ovarian morphology,
as described in the ultrasound section. The timing of re-
assessment in relation to menstrual cycles was based on
physiological maturation of the hypothalamic–pituitary
ovarian axis and the likelihood of having ovulatory cycles
matching those of women in reproductive age [26, 28,
33, 34]. Reassessment is particularly important for ado-
lescent girls with persisting PCOS features and those
with significant weight gain in adolescence and should
occur after hormonal therapy washout of at least 3
months if this therapy has been commenced (whilst en-
suring contraceptive needs are met). This recommenda-
tion is based on the need to address isolated symptoms,
such as irregular menstrual cycles or clinical hyperan-
drogenism, where the diagnosis of PCOS remains
unclear as pelvic ultrasound is not recommended at this
life stage. PCOS cannot be diagnosed during adolescence
unless both irregular menstrual cycles or hyperandro-
genism are present. It was recommended that these ado-
lescents be made aware of their ‘at risk’ status for PCOS
and that future re-evaluation may be needed if both
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features persist beyond 3 years post menarche. This rec-
ommendation emerged from published evidence as well
as from strong and consistent feedback from women
with PCOS, who had a poor diagnostic experience and
often failed to be diagnosed during adolescence,
remaining unaware of this potential diagnosis until seek-
ing treatment for infertility [11] (see Section 1.1 in the
Technical Report). Adult physicians and reproductive
endocrinologists also expressed significant concern over
delayed diagnosis. All GDGs highlighted the need to ac-
knowledge ‘risk’ yet avoid over-diagnosis or premature
labelling. Another practice point for this section is that,
in adolescents with irregular menstrual cycles and ‘at
risk’, the value and optimal timing of assessment and
diagnosis of PCOS should be discussed with the adoles-
cent and their families, considering all diagnostic chal-
lenges at this life stage as well as psychosocial and
cultural factors.
Emotional wellbeing
The first consensus recommendation was that ‘Health
professionals should be aware that, in PCOS, there is a
high prevalence of moderate to severe anxiety and de-
pressive symptoms in adults and a likely increased
prevalence in adolescence’; the second consensus recom-
mendation was that ‘Anxiety and depressive symptoms
should be routinely screened in all adolescents and
women with PCOS at diagnosis’. If the screening results
are positive, further evaluation and/or referral for assess-
ment and treatment should be completed by suitably
qualified health professionals informed by regional
guidelines. There were no evidence-based recommenda-
tions in the Guideline for the prevalence, screening,
diagnostic assessment or treatment of emotional well-
being for women or adolescents with PCOS and the
GDG provided the two strong consensus recommenda-
tions mentioned above with limited available evidence,
most of which related to studies in women and only one
study in adolescents [74, 75]. These recommendations
were based on a growing body of literature that includes
cross-sectional, longitudinal and population-based stud-
ies indicating that women with PCOS experience a high
prevalence of anxiety and depression [75–82] and the
fact that psychological issues are under-recognised [11].
According to previous and recent meta-analyses, the
odds of moderate/severe depressive symptoms were in-
creased as were the odds of moderate/severe anxiety
symptoms, independent of obesity [7, 77, 83]. Similar
evidence has started emerging in adolescent girls with
PCOS, though the data are still rather limited [74, 75].
Emotional wellbeing during adolescence was examined
in a meta-analysis and subgroup analysis observing that
adolescent girls with PCOS scored higher in depressive
and anxiety symptoms compared to controls; the
standardised mean differences for depression and anx-
iety were 0.54 (95% CI 0.16–0.93) and 0.48 (95% CI,
0.00–0.96), respectively [75]. The clinical significance of
these findings as well as the factors associated with
scores for anxiety/depression are uncertain. In adult
women with PCOS, increased BMI, insulin resistance,
hyperandrogenaemia, worse hirsutism scores and infer-
tility have been implicated in the development or exacer-
bation of depressive and anxiety symptoms [79]. Similar
studies/data are lacking for adolescents (see Section 2.2
in the Technical Report).
Given the high rates of anxiety/depression in women
with PCOS and the current evidence in adolescence, the
Guideline recommends routine screening of these condi-
tions in all adolescents and women at diagnosis, with
further evaluation if the screen is positive. Rescreening is
recommended according to medical judgement and the
patient’s progress. Often, the physical features of PCOS
can cause anxiety and depressive symptoms, yet over-
diagnosis of these psychological conditions should be
avoided whilst recognising the distress caused by PCOS
and paying attention to factors that most influence qual-
ity of life. If clinical anxiety or depression are diagnosed,
the individual should be treated according to standard
guidelines as specific studies that evaluate the effect of
psychiatric medications in PCOS are lacking (see Sec-
tions 2.8 and 2.9 in the Technical Report). The use of
psychiatric agents may worsen obesity and should be
used with caution. According to recent but limited data,
cognitive behavioural therapy may be beneficial in terms
of weight loss and symptoms of anxiety/depression in
both adolescents and women with PCOS; however, the
data merit further confirmation [83]. Similarly, initial
outcome data regarding lifestyle changes on body weight
and wellbeing in women with PCOS appear promising,
while studies in adolescents are yet to be performed. Re-
cent studies in women with PCOS indicate an increased
prevalence of disordered eating and the international
Guideline provides conditional recommendations for
awareness, assessment and appropriate therapy of disor-
dered eating [84] (see Section 2.5 in the Technical Re-
port). Whether the same applies to adolescent girls with
PCOS is yet to be determined.
Treatment
Lifestyle
Lifestyle interventions (preferably multi-component, in-
cluding diet, less sedentary behaviour, exercise and be-
havioural strategies) should be recommended in all
those with PCOS and excess weight to achieve reduc-
tions in weight, central adiposity and insulin resistance.
This was a conditional and low GRADE quality
evidence-based recommendation for lifestyle interven-
tions. Weight gain is the number one priority expressed
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by young women with PCOS [85]. Additionally, this rec-
ommendation was also based on the bidirectional associ-
ation between PCOS and weight gain, wherein there is a
high prevalence and important adverse impact of excess
weight in PCOS [86]. Obesity may induce PCOS by
worsening features and, although the concept of ‘second-
ary PCOS’ has been raised, it is still far from defined.
The same argument could apply to PCOS secondary to
other drivers of hyperinsulinemia such as type 1 dia-
betes. We could elude to an emerging concept of PCOS
secondary to other drivers of hyperinsulinaemia and
hyperandrogenism such as obesity and type 1 diabetes
[4, 87]. Vitally important was the emphasis on lifestyle
interventions to prevent excess weight gain in adoles-
cents with PCOS, avoiding waiting until obesity has de-
veloped, where lifestyle intervention alone is unlikely to
reverse the excess adiposity. Specific recommendations
on regular weighing, whilst acknowledging appropriate
sensitivities, were made. Once present, obesity exacer-
bates metabolic and psychological comorbidities in ado-
lescents with PCOS [88, 89]. Additionally, weight gain
escalates from adolescence and early adulthood requir-
ing early vigilance and intervention [90, 91]. Two sys-
tematic reviews of lifestyle interventions in women with
PCOS show improvements in weight, hyperandrogenism
and insulin resistance [92, 93]. In particular, in adoles-
cents with PCOS, a multidisciplinary model of care with
a dietitian, health psychologist and endocrinologist
showed that a behavioural intervention enhanced weight
loss when combined with dietary intervention compared
to receiving neither or dietary advice only [94].
Additionally, a randomised controlled trial (RCT) com-
paring lifestyle intervention (diet, physical activity and
behaviour) with placebo over 24 weeks had some bene-
fits in adolescents with PCOS [95] (see Chapter 3 in the
Technical Report).
Pharmacological principles of treatment in PCOS
Recommendations for the pharmacological treatment of
adolescents with PCOS include the use of the combined
oral contraceptive pill (COCP) and/or metformin in
those with a clear diagnosis or in adolescents deemed ‘at
risk’ of PCOS for the management of symptoms. These
recommendations were made following review of the
evidence for the efficacy of COCP, metformin and anti-
androgens alone or in combination for the management
of hormonal or clinical PCOS features in adolescents
and adult women with PCOS. These recommendations
were also based on the need for interventions and longi-
tudinal follow-up to address PCOS symptoms in adoles-
cents who are ‘at risk’ but do not yet meet full
diagnostic criteria. Whilst diagnosis is recommended
where both irregular menstrual cycles and hyperandro-
genism are present, when only one of these is detected,
symptom reduction and future reassessment was
deemed preferable to prematurely labelling or over-
diagnosing an adolescent as having PCOS. This
approach addressed the conundrum that healthcare pro-
fessionals involved in the medical management of ado-
lescent girls face in potentially over-diagnosing normal
pubertal girls, girls with transient menstrual irregular-
ities, or under-diagnosing girls who will likely evolve to
a PCOS phenotype. Additionally, medications such as
COCP are commonly prescribed in adolescents for
contraception and other indications.
The following practice points should apply to all medi-
cations used in PCOS to inform adolescents and their
families and to guide health professionals when consid-
ering or recommending pharmacotherapy: (1) an
individual’s personal characteristics, preferences and
values are of importance when recommending pharma-
cotherapy; (2) the benefits, adverse effects and contrain-
dications in PCOS and in general populations should be
considered; and (3) the fact that COCPs, metformin and
other pharmacological treatments are generally ‘off-label’
for the treatment of PCOS should be discussed where
allowed, with adolescents and their families to consider
the evidence and potential side effects for each option.
However, off-label use is predominantly evidence based
for other conditions and is allowed in many countries.
Off-label prescribing occurs when a medication is pre-
scribed for an indication, a route of administration, or a
patient group that is not included in the approval prod-
uct information document for that medication by the
relevant regulatory body. Prescribing off-label is un-
avoidable and most commonly means that there has not
been a submission to request evaluation of the indication
or of that patient group for any given medication. The
latter is very common in paediatric practice. Off-label
use of metformin in adolescents with PCOS has been
described [96].
Holistic approaches are required and pharmacotherapy
in PCOS should be considered alongside education and
counselling, lifestyle, and other options, including cos-
metic therapy. Of note, the Guideline did not review the
evidence on cosmetic therapies for hirsutism or non-
hormonal therapies for acne.
Medications
1. COCP (oestrogen and progestin preparations)
The COCP alone should be considered in adolescents
with a clear PCOS diagnosis or could be considered in
those deemed ‘at risk’ but not yet diagnosed with PCOS
in both groups for the management of clinical hyperan-
drogenism and/or irregular menstrual cycles. These two
conditional and low GRADE quality evidence-based
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recommendations were based on limited evidence in ad-
olescents, including two RCTs [95, 97] and a meta-
analysis [98]. The latter evaluated the effect of metfor-
min versus the COCP and included four RCTs [95, 99–
101] with a total of 170 adolescents aged 12–21 years,
showing improvements in menstrual irregularities and
acne. The RCTs were of 6-months duration with the ex-
ception of one, which was of 24 months [101] (see Sec-
tion 4.2 and 4.3 in the Technical Report). Evidence on
COCP use from the general population also informed
the Guideline by including considerations of adverse
effects. Although the COCP is relatively safe, there are
absolute medical contraindications to consider according
to World Health Organisation Guidelines such as history
of migraine with aura, deep vein thrombosis, pulmonary
embolism, known thrombogenic mutations, multiple risk
factors for cardiovascular disease, breast cancer, neur-
opathy, severe cirrhosis and malignant liver tumours
[102]. Smoking and obesity are also risk factors for deep
vein thrombosis; however, the absolute risk of these
complications in adolescents remains very low.
Specific types or doses of progestins, oestrogens or
combinations of COCP cannot currently be recom-
mended due to insufficient data among women and ado-
lescents with PCOS. Practice should be informed by
general population guidelines. This was a conditional
and low GRADE quality evidence-based recommenda-
tion in relation to the use of specific types of COCP and
was based on evidence of COCP use in the general
population and World Health Organisation Guidelines
as there were no trials evaluating this in women or ado-
lescents with PCOS (see Section 4.2 and 4.3 in the Tech-
nical Report). A practice point for this section includes
that COCPs with 35 μg of ethinylestradiol and cyproter-
one acetate should not be used as first-line therapy due
to the absence of evidence of greater efficacy and the
presence of higher risks, including deep venous throm-
bosis. All COCPs are associated with an increased risk of
deep venous thrombosis, but the risk is higher with
COCPs containing 30–35 μg of ethinylestradiol and ges-
todene, desogestrel, cyproterone acetate or drospirenone
when compared to the COCP containing 30 μg of
ethinylestradiol with levonorgestrel, norethisterone (nor-
ethindrone) or norgestimate. Lower-risk COCP prepara-
tions should be recommended as first-line therapy [103].
2. Combined COCP and metformin
The COCP in combination with metformin could be
considered in adolescents with PCOS and a BMI > 25
kg/m2 where the COCP and lifestyle changes do not
achieve desired goals. This was a conditional and low
GRADE quality evidence-based recommendation based
on a single RCT including 79 adolescents followed over
6 months [95] and supported by 6 RCTs in adult women
that highlighted the differential effects according to BMI
categories [104]. Although the combination of metfor-
min and the COCP offers additional benefits, these did
not surpass the impact of the COCP plus lifestyle inter-
ventions and hence the combination was indicated when
the COCP and lifestyle interventions have failed to meet
the treatment goals. Since the COCP in combination
with metformin lead to mild gastrointestinal side effects,
these potential side effects need to be discussed with the
adolescent and her family (see Section 4.2 and 4.3 in the
Technical Report).
3. Metformin
Metformin in addition to lifestyle interventions could
be considered in adolescents with a clear PCOS diagno-
sis or with symptoms of PCOS before a diagnosis is
made. This was a conditional low GRADE quality
evidence-based recommendation based on a meta-
analysis evaluating the effect of metformin versus pla-
cebo in women with PCOS. This meta-analysis included
20 RCTs (one RCT in adolescents [95]) and highlighted
the beneficial effects of metformin on BMI, waist-to-hip
ratio and triglycerides. Metformin doses used in the
meta-analysis trials were 1500–1700mg per day. Side ef-
fects were only reported in five RCTs and included mild
to moderate gastrointestinal side effects that were self-
limiting (nausea, vomiting, diarrhoea, abdominal pain
and non-specified gastrointestinal disturbances). There
were no reports on vitamin B12 levels in the trials in-
cluded in the meta-analysis. Additionally, there were
three RCTs (one RCT in adolescents [95]) evaluating the
effect of metformin versus lifestyle interventions, which
showed improvements in testosterone levels with met-
formin but with very low certainty in effect estimates.
There was also a meta-analysis that evaluated metformin
versus COCP in adolescents with PCOS, which included
four RCTs [95, 99–101] and showed that metformin at a
dose of 1700–2000 mg per day was associated with an
improvement in BMI when compared to the COCP [98].
There were no studies in adolescents evaluating the ef-
fects of different doses of metformin; the only study that
evaluated this in 68 adult women with PCOS did not re-
port a difference in weight effects when using 1500 mg
or 2550mg a day of metformin [105] (see Section 4.4 in
the Technical Report).
4. Antiandrogens
Recommendations suggest the use of the COCP alone
with cosmetic therapy for at least 6 months prior to con-
sidering antiandrogens. Where COCPs are contraindi-
cated or poorly tolerated, and in the presence of
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effective forms of contraception, antiandrogens could
be considered to treat hirsutism or androgen-related
alopecia. The use of effective contraception is essen-
tial due to the teratogenic potential of antiandrogens
and their impairment of external genital development
in male foetuses. This conditional evidence-based rec-
ommendation of very low GRADE quality was based
mainly on studies in adult women and included the
use of flutamide, finasteride or spironolactone alone
or in combination with a diet intervention [106–110].
The reported side effects were gastrointestinal, includ-
ing mild elevation of transaminases. There was only
one study including a small number of adolescents
with PCOS (n = 14) that evaluated finasteride, but it
lacked a direct comparison between groups and did
not report side effects [111]. There was insufficient
evidence to make an evidence-based recommendation
in relation to efficacy of specific types of antiandro-
gens; the trials included small numbers of subjects
and some were not RCTs (see Section 4.6 in the
Technical Report). This recommendation was also in-
formed by the Endocrine Society guidelines for the
management of hirsutism, which recommend the use
of cosmetic and COCP therapy as the first-line treat-
ment for hirsutism in women with PCOS [112].
Models of care and transition
There was no evidence-based recommendation as the
systematic search did not identify any studies evaluating
any type of models of care. A practice point for this sec-
tion recommended that interdisciplinary care needs to
be considered for those with PCOS where appropriate
and available. Primary care is generally well placed to
diagnose, screen and coordinate interdisciplinary care
considering that women with PCOS face multiple health
problems across the lifespan and see multiple health
professionals. Differences in healthcare systems and set-
tings, including rural or urban areas and developing
countries, as well as primary care system differences in
developed countries were acknowledged. The coordin-
ation of interdisciplinary care also allows the screening
and management of comorbidities associated with
PCOS. Four studies have described models of care in
adult women with PCOS in terms of barriers, enablers
and patient/healthcare provider satisfaction [113–116].
There were no studies in adolescents with PCOS nor
any studies evaluating outcomes following the transition
from paediatric to adult care (see Section 2.6 in the
Technical Report). Transition to adult care is required
not only for adolescents with a clear diagnosis of PCOS
but also for adolescents ‘at risk’ of PCOS to ensure their
re-evaluation at an appropriate time to review PCOS
diagnosis and management.
Discussion
The Guideline recommendations are the result of exten-
sive international engagement and rigorous, evidence-
based processes aligned with international best practice.
Whilst the Guideline provided recommendations for
adult women and adolescents, this paper summarises the
evidence and recommendations relating to adolescents
as defined by the World Health Organisation, namely as
females aged between 10 and 19 years. It also addresses
recommendations relating to gynaecological age, and
specifically 8 years post menarche, and the use of pelvic
ultrasound in PCOS diagnosis as well as recommenda-
tions relating to the re-evaluation of girls that do not
meet the diagnostic criteria in adolescence but are con-
sidered ‘at increased risk’ of PCOS. There are few
evidence-based recommendations relating to adolescents
in the Guideline highlighting the limited evidence in this
age group. Limitations within studies included poorly
defined study populations, challenges in diagnosis
around puberty, the different diagnostic criteria used
and lack of availability of data for “time post menarche”
of subjects included in most of the studies. Research rec-
ommendations highlighted these gaps and emphasised
the need for greater high-quality research of PCOS dur-
ing adolescence.
Diagnosis
The controversies of diagnosing adolescents with PCOS
are compounded by a reliance on 95th centiles cut-off
points for menstrual cycles or hirsutism, which are not
diagnostic of pathology and are derived from highly vari-
able populations and relatively poor-quality data. Add-
itionally, there is a lack of available outcome data on the
long-term health impact of PCOS in conditions such as
diabetes. Moving forward, there is a need for greater re-
search into how the confluence of diagnostic factors can
be separated out to establish a clear clinical syndrome
and how these factors predict short- and long-term ad-
verse health outcomes, with studies in this area now
underway.
Diagnosis relied on strong consensus recommenda-
tions and aimed to avoid delayed, under- or over-
diagnosis of PCOS during adolescence. The criteria in-
cluded a clear definition of irregular menstrual cycles
according to time post menarche and clinical hyperan-
drogenism, including severe acne and hirsutism and/or
biochemical hyperandrogenism, after exclusion of other
conditions that mimic PCOS. The use of pelvic ultra-
sound for diagnosis in females less than 8 years post me-
narche should be avoided due to the overlap with
normal pubertal physiology, the lack of specificity of
polycystic ovarian morphology for PCOS diagnosis in
this age group and the avoidance of transvaginal ultra-
sound in those not yet sexually active. AMH was not
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recommended for a diagnosis of PCOS due to a lack of
evidence and apparent lack of specificity. Additionally,
special considerations need to be given when assessing
adolescents for PCOS; importantly, adolescents’ and
their family’s preferences and cultural norms should be
included in decision-making.
The Guideline recommends recognising adolescents ‘at
risk’. The potential for over-diagnosis is minimised by the
narrowed diagnostic criteria; however, there is also re-
spectful recognition of the need to avoid delayed and
missed diagnosis and a poor diagnosis experience. As
such, reassessment is recommended at 3 years post me-
narche in relation to menstrual irregularity and at 8 years
post menarche in relation to the use of pelvic ultrasound
to review the polycystic ovarian morphology. This ap-
proach recognises a group of adolescents with only one
symptom cluster as ‘at risk’ of PCOS, enabling a focus on
symptom management whilst avoiding premature label-
ling and recommending subsequent follow-up.
Emotional wellbeing
Following a diagnosis of PCOS, healthcare providers
should be aware of the likely increased risk of anxiety
and depressive symptoms that will benefit from appro-
priate screening and management. General Guidelines
for the assessment and management of these conditions
in children and adolescents should be used as there is
no specific data referring to adolescent girls with PCOS.
Emotional wellbeing is a poorly evaluated area in adoles-
cent girls with PCOS. Clearly, more research is needed
to determine the pathophysiology, whether the symp-
toms start early in adolescence, the optimal treatment
and whether these symptoms will influence engagement
with management strategies as observed in adult women
with PCOS.
Treatment
Multicomponent lifestyle interventions (diet, exercise,
less sedentary behaviour and behavioural strategies) are
the first line of treatment, vital in preventing excess
weight gain as well as targeting weight management
from adolescence. Pharmacologic management for non-
fertility indications in PCOS included evidence-based
recommendations with data in adolescents. The treat-
ment options for girls considered to be ‘at risk’ of PCOS
and those with a clear diagnosis of PCOS include the
COCP and metformin. The COCP is recommended for
the management of irregular menstrual cycles and/or
hyperandrogenism, whereas metformin alone or in com-
bination with the COCP is recommended to manage
weight and metabolic comorbidities.
Recognition of a group who are at risk of PCOS but
do not meet all diagnostic criteria allows the treatment
of adolescent girls with symptoms yet acknowledges the
need for future reassessment at or before 8 years post
menarche should PCOS features persist. It also high-
lights the need for appropriate transition from paediatric
to adult care.
Strengths and limitations
The strengths of the Guideline include the extensive
international engagement and rigorous processes aligned
with international best practice, including systematic evi-
dence review and synthesis (AGREE II, GRADE, Na-
tional Health and Medical Research Council (NHMRC)
and European Society of Human Reproduction and
Embryology (ESHRE) criteria), extensive consultation
and partnership at all stages with those affected by
PCOS and interdisciplinary health professionals and ex-
perts, GDG meetings, integration and response to feed-
back from international consultation across 37 societies,
and the latest updates in key evidence raised during pub-
lic consultation.
A limitation of the Guideline is the lack of a formal
analysis of cost effectiveness or economic feasibility;
however, the potential impact of cost was considered in
the GRADE process. Furthermore, the Guideline
followed priorities that were mostly derived from women
with PCOS, not adolescents with PCOS (this will be ad-
dressed in the next update of the guideline), whilst the
group of multidisciplinary healthcare professionals in-
cluded paediatricians.
Overall, the evidence considered by the Guideline
around adolescence was of low to moderate quality and
highlighted the need for future high quality research, in-
cluding longitudinal studies, to identify the early predic-
tors and natural history of PCOS in adolescents and to
allow for timely diagnosis and appropriate management
during adolescence and in the transition to adult care.
Most importantly, the Guideline refined the diagnostic
criteria based on the best available evidence and consen-
sus input from all stakeholders and should allow a more
accurate diagnosis of adolescent girls with PCOS.
Translation
The aim of the comprehensive research translation
programme that accompanied the release of the Guide-
line was to improve the timely and accurate diagnosis
and management as well as to augment the consistent
implementation of evidence-based care worldwide. A re-
cent Cochrane review demonstrates that obtaining
patient-provided information improves adherence with
guidelines and evidence-based care [117]. Hence, the
Guideline translation encompassed a range of co-
designed outputs developed with both women and
health professionals, including the freely available and
rigorously developed AskPCOS app, which is based on
the Guideline and is now used across 112 countries. It
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provides personalised information and a question
prompt list for those with PCOS and their families to
optimise health professional engagement. The app also
provides health literacy-enhancing tools, comprehensive
PCOS-related health information, internationally accre-
dited and accessible health professional-accredited
courses on the FutureLearn platform, webinars with
international expert panels, and freely available e-health
information resources [19, 118]. The guideline and re-
sources are available in a range of languages, proven to
be important in guideline uptake [119]. This translation
initiative contributes to improved patient experience and
serves as an exemplar for international collaborative en-
gagement and healthcare impact.
Conclusion
Extensive international engagement and rigorous pro-
cesses have refined the diagnostic criteria to avoid the
delayed, under- or over-diagnosis of PCOS and have
clarified the treatment of PCOS during adolescence. The
Guideline is supported by a multifaceted international
translation programme with co-designed resources to
educate health professionals and empower adolescents
and women with PCOS, including an integrated and
comprehensive evaluation programme. However, the evi-
dence synthesis and guideline process highlighted the
need for further research on PCOS during adolescence.
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